Resistance to visceral leishmaniasis: New mechanisms involved

May 16, 2013, CNRS

Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD have elucidated new molecular mechanisms involved in resistance to visceral leishmaniasis, a serious parasitic infection. They have shown that dectin-1 and mannose receptors participate in the protection against the parasite responsible for this infection, by triggering an inflammatory response, while the DC-SIGN receptor facilitates the penetration of the pathogen and its proliferation in macrophages. This work, conducted on both mice and humans and published on 16 May 2013 in the journal Immunity, opens new perspectives for the prevention and treatment of this disease.

Leishmaniasis is one of the most serious fatal parasitic infections in the world: 1.5 to 2 million infected individuals are recorded every year, of which 500,000 involve cases of visceral leishmaniasis. This chronic disease is a public health problem in Latin America, Asia, Africa, and more recently, southern Europe.

Leishmania, the parasite responsible for the infection, colonizes the where it proliferates. Dectin-1, mannose and DC-SIGN are three receptors of the C-type lectin family, present on the surface of macrophages. Depending on their state of differentiation, they can either contribute to eliminating the parasite or instead facilitate its proliferation by hijacking the defence mechanisms of the macrophage to the parasite's advantage and thus bring about infection. These cells therefore represent a major target in the defence of the host against the pathogen.

This work, conducted by research teams from the Laboratoire Pharmacochimie et Pharmacologie pour le Développement (Université Toulouse III - Paul Sabatier/IRD) and the Institut de Pharmacologie et de Biologie Structurale (CNRS/Université Toulouse III - Paul Sabatier), was initially carried out on mice then on . It shows that dectin-1 and mannose have an inhibiting effect on the parasite. In fact, they trigger the production of oxygenated free radicals and inflammatory mediators, thereby helping to eliminate the parasite. The researchers also highlighted the opposite role of the DC-SIGN receptor, which participates in the phagocytosis of Leishmania and favors its proliferation by inhibiting macrophage microbicidal activity.

Confirmed in humans, these results also show for the first time that C-type lectins control the balance between pro-inflammatory and anti-inflammatory lipid mediators, contributing to the orientation of the anti-parasitic defence.

This discovery represents a breakthrough in infectious diseases and could pave the way for the development of new medicines.

Explore further: Rare human parasite found in US horse for the first time, researchers report

More information: Lefevre, L. et al. Divergent roles for C-type lectin receptors in the modulation of host cell response to Leishmania infantum, Immunity, 16 May 2013.

Related Stories

Rare human parasite found in US horse for the first time, researchers report

November 16, 2012
(Medical Xpress)—A rare, potentially fatal species of parasite never before found in North America has been identified in a Florida horse.

Kala-azar treatment failing in Nepal

March 1, 2013
In a recent study, scientists have concluded that the cure rates of Miltefosine, the only oral drug for visceral leishmaniasis available, have significantly decreased. Miltefosine was introduced in the Indian subcontinent ...

Recommended for you

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.

How the immune system's key organ regenerates itself

January 15, 2018
With advances in cancer immunotherapy splashing across headlines, the immune system's powerful cancer assassins—T cells—have become dinner-table conversation. But hiding in plain sight behind that "T" is the organ from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.